In this issue:
- Higher vs standard adalimumab induction and maintenance for UC
- Upadacitinib for moderately to severely active UC
- IBD and CVD
- Sodium butyrate effectiveness in children and adolescents with IBD
- Surgery rates in CD treated with vedolizumab or ustekinumab
- Vedolizumab for the treatment of chronic pouchitis
- Prediction of CD stricturing phenotype
- NAFLD risk factor for thiopurine hepatotoxicity in CD
- Frailty and IBD
- Management of IBD in the elderly
- Science blog: Biosimilars in IBD
Please login below to download this issue (PDF)